Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C82.-C82.7C82.9C83.3C84.4C84.6C84.7C85.2C86.1C86.2C86.5C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, T-CellSequenceSTUDY - levelChemotherapyChemo-substanceCisplatinDexamethasoneGemcitabineNivolumabOxaliplatinRituximabChemo-substanceCisplatinDexamethasoneGemcitabineNivolumabOxaliplatinRituximabChemo-substanceCisplatinDexamethasoneGemcitabineNivolumabOxaliplatinRituximabChemo-substanceCisplatinDexamethasoneGemcitabineNivolumabOxaliplatinRituximabNo. Substances1234 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideNo. Substances1710Protocol classificationTherapy classificationalternativeStudy protocol, currentIntensityStandard doseTherapy indicationSecond lineTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaInfectionsThromboembolic EventVomiting only studiesPublicationAuthorCrump MHeld GDiseaserezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3OriginInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Princess Margaret Cancer Centre, Ontario, CanadaProtocols in Revision 5 protocols foundProtocols under revision.R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
